Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSStandard

CINVANTI

APREPITANT

Standard Dose
130MG/18ML (7.2MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview CINVANTI is listed in Drugs@FDA under application 209296 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient APREPITANT Form and strength EMULSION;INTRAVENOUS - 130MG/18ML (7.2MG/ML) Sponsor HERON THERAPS INC Submission history Latest submission status date: 2024-03-05 00:00:00.

Structured Monograph

Clinical summary

Approval overview CINVANTI is listed in Drugs@FDA under application 209296 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient APREPITANT Form and strength EMULSION;INTRAVENOUS - 130MG/18ML (7.2MG/ML) Sponsor HERON THERAPS INC Submission history Latest submission status date: 2024-03-05 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.